Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab"

Affiliations

• ¹ Department of Gastroenterology and Hepatology, Okayama University Hospital, Okayama, Japan.
• ² Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
• ³ Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
• ⁴ Department of Gastroenterology, Okayama Saiseikai General Hospital, Okayama, Japan.
• ⁵ Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
• ⁶ Department of Gastroenterology, Hiroshima City Hospital, Hiroshima, Japan.
• ⁷ Department of Gastroenterology, Mitoyo General Hospital, Kanonji, Japan.
• ⁸ Department of Gastroenterology, Sumitomo Besshi Hospital, Niihama, Japan.
• ⁹ Department of Gastroenterology, Kurashiki Central Hospital, Kurashiki, Japan.
• ¹⁰ Department of Gastroenterology, Japanese Red Cross Himeji Hospital, Himeji, Japan.
• ¹¹ Department of Gastroenterology, Fukuyama City Hospital, Fukuyama, Japan.
• ¹² Department of Gastroenterology, Fukuyama Medical Center, Fukuyama, Japan.